Table 2.
Subgroup risk factor and rCBF analysis.
| MMD (MOCA ≥ 26) | MMD (MOCA < 26) | P | ||
|---|---|---|---|---|
| Sex (F:M) | 21:17 | 37:40 | 0.467 | |
| Age, y | 34.42 ± 10.59 | 41.69 ± 11.71 | 0.003 | |
| Education, y | 13.89 ± 2.56 | 12.47 ± 2.80 | 0.013 | |
| Clinical presentations | 0.614 | |||
| TIA | 24 | 55 | ||
| Headache | 4 | 5 | ||
| Asymptomatic | 10 | 17 | ||
| Medical history, n(%) | ||||
| Diabetes mellitus | 4 | 8 | 1.000 | |
| Hypertension | 12 | 35 | 0.155 | |
| Hyperlipidemia | 5 | 15 | 0.400 | |
| Hyperhomocysteinemia | 8 | 18 | 0.779 | |
| Fazekas classification | 0.02 | |||
| 0 | 27 | 37 | ||
| 1 | 11 | 40 | ||
| Time from first onset to admission(months) | 11.92 ± 16.59 | 22.01 ± 41.19 | 0.174 | |
| Suzuki stage | ||||
| Left | 0.296 | |||
| 1–2 | 9 | 29 | ||
| 3–4 | 17 | 31 | ||
| 5–6 | 12 | 17 | ||
| Right | 0.835 | |||
| 1–2 | 13 | 22 | ||
| 3–4 | 18 | 41 | ||
| 5–6 | 7 | 14 | ||
| mRs | 0.202 | |||
| 0 | 3 | 1 | ||
| 1 | 35 | 76 | ||
| rCBF of ROI | ||||
| L-LFC | 1.44 ± 0.25 | 1.34 ± 0.30 | 0.026 | |
| L-MFC | 1.58 ± 0.36 | 1.56 ± 0.36 | 0.369 | |
| L-CSO | 0.60 ± 0.15 | 0.51 ± 0.13 | 0.002 | |
| L-PC | 1.41 ± 0.40 | 1.33 ± 0.33 | 0.277 | |
| L-TC | 1.27 ± 0.43 | 1.13 ± 0.32 | 0.216 | |
| R-LFC | 1.48 ± 0.34 | 1.41 ± 0.32 | 0.234 | |
| R-MFC | 1.58 ± 0.32 | 1.57 ± 0.29 | 0.909 | |
| R-CSO | 0.56 ± 0.12 | 0.50 ± 0.13 | 0.019 | |
| R-PC | 1.38 ± 0.30 | 1.33 ± 0.33 | 0.166 | |
| R-TC | 1.34 ± 0.42 | 1.21 ± 0.33 | 0.108 | |
rCBF: relative cerebral blood flow: CBF values of the associated cortex/ipsilateral cerebellum; L: left; r: right, LFC: lateral frontal cortex; MFC: medial frontal cortex; CSO: centrum semi-oval; PC: parietal cortex; TC temporal cortex.